Across TCGA pan-cancer cohorts, MRPS18C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MRPS18C data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MRPS18C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPS18C expression acts as an unfavorable survival marker.
KIRC and COAD are the cancer types where MRPS18C Mutation most reproducibly stratifies survival.